3611 Valley Centre Drive
About Travere Therapeutics
Even with the challenges all of us are facing as a result of COVID-19, Travere Therapeutics continues to come together as an organization to live our mission each day to support our patients and invest in our capabilities for the future. At the center of these efforts are our people. Travere remains committed to preventing interruption of our clinical programs, providing unwavering patient support and ensuring delivery of therapies to our patients. Moments like this are when our patients need us the most.
If you want to join a team that now more than ever lives its mission to the fullest extent, please review our current opportunities and apply to positions that may be of interest to you.
Travere is continuing to hire for all open roles with all interviewing and onboarding done virtually due to COVID-19.
Everyone new to the team, along with our current staff, will temporarily work from home until it is safe to return to our offices.
At Travere Therapeutics, formerly Retrophin, our number one priority will always be the patients we serve - they are “why” we come to work each day. Our Why is ingrained into our culture and is paramount to “what” we do every day and “how” we do it to achieve our mission of identifying, developing and delivering life-changing therapies to people living with rare disease. By working hard, supporting our team members and living our values of Accountability, Entrepreneurial Spirit, Integrity, Patient Focus, Scientific Excellence and Teamwork, we strive to help our organization succeed and pursue our vision - to become a preeminent, global and fully-integrated biopharmaceutical company within the rare disease community that is dedicated to giving patients a chance and providing hope.
Our pipeline features late-stage development programs targeting rare diseases with significant unmet medical needs including sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. In partnership with leaders in patient advocacy and government research, we are also working to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, rare conditions with no approved treatment options. Our R&D efforts are supported by revenues from our four commercial products Chenodal® (chenodiol), Cholbam® (cholic acid), Thiola® (tiopronin) and THIOLA EC™ (tiopronin) delayed-release tablets.
Through our portfolio of approved products and promising pipeline focused on hepatology, nephrology and neurology, we strive to help people achieve the best possible outcomes today and tomorrow. But most importantly, it is the commitment of our experienced, knowledgeable and compassionate team members, who put patients at the center of everything they do, that truly matters.
Currently, there are no jobs for this employer on BioSpace.
Browse jobs with BioSpace Featured Employers here.